Alu, A., Lei, H., Han, X., Wei, Y. & Wei, X. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. J. Hematol. Oncol. 15, 138 (2022).

Article  CAS  Google Scholar 

Krämer, J., Bar-Or, A., Turner, T. J. & Wiendl, H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat. Rev. Neurol. 19, 289–304 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Wang, Y., Zhang, L. L., Champlin, R. E. & Wang, M. L. Targeting Bruton’s tyrosine kinase with ibrutinib in B-cell malignancies. Clin. Pharmacol. Ther. 97, 455–468 (2015).

Article  CAS  PubMed  Google Scholar 

Davids, M. S. & Brown, J. R. Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase. Future Oncol. 10, 957–967 (2014).

Article  CAS  PubMed  Google Scholar 

Advani, R. H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31, 88–94 (2012).

Article  PubMed  PubMed Central  Google Scholar 

Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32–42 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Byrd, J. C. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371, 213–223 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Burger, J. A. et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N. Engl. J. Med. 373, 2425–2437 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barr, P. M. et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 6, 3440–3450 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507–516 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Claro, R. A. et al. FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin. Cancer Res. 21, 3586–3590 (2015).

Article  PubMed  Google Scholar 

Treon, S. P. et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N. Engl. J. Med. 372, 1430–1440 (2015).

Article  CAS  PubMed  Google Scholar 

Noy, A. et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 129, 2224–2232 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Estupinan, H. Y., Berglof, A., Zain, R. & Smith, C. I. E. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front. Cell Dev. Biol. 9, 630942 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Wang, M. L. et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N. Engl. J. Med. 386, 2482–2494 (2022).

Article  CAS  PubMed  Google Scholar 

Wang, M. et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 391, 659–667 (2018).

Article  CAS  PubMed  Google Scholar 

Wang, M. et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 33, 2762–2766 (2019).

Article  CAS  PubMed  Google Scholar 

Le Gouill, S. et al. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors. Haematologica 109, 343–350 (2024).

PubMed  Google Scholar 

Wang, M. et al. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: results from the phase 3, double-blind, placebo-controlled ECHO trial. EHA Library LB3439 https://library.ehaweb.org/eha/2024/eha2024-congress/4136515/michael.wang.acalabrutinib.plus.bendamustine.and.rituximab.in.untreated.mantle.html (2024).

AstraZeneca. Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO phase III trial. News release. https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-combination-improved-pfs-in-1l-mcl.html (2024).

FDA. FDA grants accelerated approval to zanubrutinib for mantle cell lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma (2019).

Zhou, K. et al. Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. J. Hematol. Oncol. 14, 167 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tam, C. S. et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 5, 2577–2585 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song, Y. et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood 139, 3148–3158 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karr, M. & Roeker, L. A history of targeted therapy development and progress in novel-novel combinations for chronic lymphocytic leukemia (CLL). Cancers 15, 1018 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kay, N. E., Hampel, P. J., Van Dyke, D. L. & Parikh, S. A. CLL update 2022: a continuing evolution in care. Blood Rev. 54, 100930 (2022).

Article  PubMed  Google Scholar 

Benjamini, O. et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk. Lymphoma 56, 1643–1650 (2015).

Article  CAS  PubMed  Google Scholar 

Chatzikonstantinou, T. et al. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. EClinicalMedicine 65, 102307 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Munir, T. et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am. J. Hematol. 94, 1353–1363 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Itsara, A. et al. Long-term outcomes in chronic lymphocytic leukemia treated with ibrutinib: 10-year follow-up of a phase 2 study. Blood 142, 201 (2023).

Article  Google Scholar 

Ghia, P. et al. Acalabrutinib versus investigator’s choice in relapsed/refractory chronic lymphocytic leukemia: final ASCEND trial results. Hemasphere 6, e801 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharman, J. P. et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia 36, 1171–1175 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharman, J. P. et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 395, 1278–1291 (2020).